Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text




What We Know Today About Alzheimer's Disease

About Alzheimer's Inside the Brain Causes Treatments

Current Alzheimer's Treatments

Although there is no cure, Alzheimer's medications can temporarily slow the worsening of symptoms and improve quality of life for those with Alzheimer's and their caregivers.

FDA-approved drugs

The U.S. Food and Drug Administration (FDA) has approved five medications (listed below) to treat the symptoms of Alzheimer's disease.

Drug name

Brand name

Approved For

FDA Approved

1. donepezil Aricept All stages 1996
2. galantamine Razadyne Mild to moderate 2001
3. memantine Namenda Moderate to severe 2003
4. rivastigmine Exelon All stages 2000
5. donepezil and memantine Namzaric Moderate to severe 2014

How Alzheimer's drugs work

To understand how Alzheimer's medications work, you first need to understand the communication network in the brain. The picture below depicts nerve cells, or neurons, in the brain. Neurons are the chief cells destroyed by Alzheimer's disease.

Roll your mouse over the red text to highlight the image.

In the brain, neurons connect and communicate at synapses, where tiny bursts of chemicals called neurotransmitters carry information from one cell to another. Alzheimer's disrupts this process, and eventually destroys synapses and kills neurons, damaging the brain's communication network.

Current FDA-approved Alzheimer's drugs support this communication process through two different mechanisms:

1) Cholinesterase inhibitors work by slowing down the process that breaks down a key neurotransmitter. Donepezil, galantamine and rivastigmine are cholinesterase inhibitors.

2) Memantine, the fifth Alzheimer's drug, is an NMDA (N-methyl-D-aspartate) receptor antagonist, which works by regulating the activity of glutamate, an important neurotransmitter in the brain involved in learning and memory. Attachment of glutamate to cell surface "docking sites" called NMDA receptors permits calcium to enter the cell. This process is important for cell signaling, as well as learning and memory. In Alzheimer’s disease, however, excess glutamate can be released from damaged cells, leading to chronic overexposure to calcium, which can speed up cell damage. Memantine helps prevent this destructive chain of events by partially blocking the NMDA receptors.

The effectiveness of cholinesterase inhibitors and memantine varies across the population.

Catalyst to progress

The first Alzheimer's Association grants, awarded in 1982, included a study exploring the nerve cell communication network targeted by cholinesterase inhibitors, today's manstay of drug treatment. Association-funded work has contributed important insights to the knowledge base supporting virtually every FDA-approved and investigational Alzheimer's treatment. Learn more about our commitment to research.

Back to top

Future treatment breakthroughs

Researchers are looking for new ways to treat Alzheimer's. Current drugs help mask the symptoms of Alzheimer's, but do not treat the underlying disease or delay its progression. A breakthrough Alzheimer's drug would treat the underlying disease and stop or delay the cell damage that eventually leads to the worsening of symptoms. There are several promising drugs in development and testing, but we need more volunteers to complete clinical trials of those drugs and increased federal funding of research to ensure that fresh ideas continue to fill the pipeline.

Sign up for our weekly e-newsletter
Stay up-to-date on the latest advances in Alzheimer's treatments, care and research. Subscribe now

Related links

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.